Physician profile
Amy S Lang
NPI 1104850486
$4,966.97
in general payments reported to CMS, 2019-2025
30 companies · $1,848 in 2025
The $1,848 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,346 · 2020: $519 · 2021: $161 · 2023: $224 · 2024: $870 · 2025: $1,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,530 · Food and Beverage: $1,399 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,529.72 |
| Food and Beverage | $1,399.46 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,910.95 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $642.32 | 2019-2025 | Enhertu |
| Pfizer INC. | $351.37 | 2019-2025 | |
| Daiichi Sankyo INC. | $253.21 | 2019-2025 | Enhertu, Injectafer |
| Amgen INC. | $195.67 | 2019-2023 | Xgeva, Nplate |
| Lilly USA, LLC | $194.62 | 2019-2025 | Verzenio |
| Tersera Therapeutics LLC | $185.13 | 2019-2024 | Zoladex |
| Genentech USA, INC. | $171.78 | 2019-2025 | Itovebi, Venclexta, Tecentriq |
| Gilead Sciences, INC. | $160.30 | 2021-2025 | Trodelvy |
| Puma Biotechnology, INC. | $137.26 | 2019-2025 | |
| Eisai INC. | $113.37 | 2019-2020 | |
| Foundation Medicine, INC. | $77.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $76.09 | 2019-2024 | Lynparza, Keytruda |
| Stemline Therapeutics INC. | $62.77 | 2023-2024 | Orserdu |
| Astellas Pharma US INC | $55.37 | 2024-2025 | Vyloy, Xospata |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $51.91 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $44.67 | 2019-2020 | |
| Celgene Corporation | $34.78 | 2019 | |
| Incyte Corporation | $33.43 | 2024-2025 | Jakafi, Monjuvi |
| Sobi, INC | $26.39 | 2025 | |
| Morphosys, US INC. | $24.74 | 2024 | Monjuvi |
| Janssen Biotech, INC. | $22.85 | 2019 | |
| Tactile Systems Technology INC | $21.88 | 2023 | Entre Plus, Flexitouch Plus |
| Spectrum Pharmaceuticals INC. | $20.65 | 2024 | Rolvedon |
| E.R. Squibb & Sons, L.L.C. | $19.76 | 2019 | |
| Abbvie INC. | $18.68 | 2020 | |
| Karyopharm Therapeutics INC. | $16.58 | 2023 | Xpovio |
| Helsinn Therapeutics (U.S.), INC. | $16.16 | 2019 | |
| Tempus Ai, INC | $14.71 | 2024 | |
| Macrogenics, INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.